Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03686488
Title TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Ramucirumab + Trifluridine-tipiracil hydrochloride

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.